These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 12204181)
1. Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin. Medeiros EA Braz J Infect Dis; 2002 Aug; 6(4):149-56. PubMed ID: 12204181 [TBL] [Abstract][Full Text] [Related]
2. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections. Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study. Franca SA; Carvalho CR Braz J Infect Dis; 2002 Aug; 6(4):157-63. PubMed ID: 12204182 [TBL] [Abstract][Full Text] [Related]
4. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. Nicholson SC; High KP; Gothelf S; Webb CD Diagn Microbiol Infect Dis; 2002 Sep; 44(1):109-16. PubMed ID: 12376040 [TBL] [Abstract][Full Text] [Related]
5. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Pfaller MA; Jones RN Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036 [TBL] [Abstract][Full Text] [Related]
6. Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. Nicholson SC; Webb CD; Andriole VT; Jones RN; Wilson WR Diagn Microbiol Infect Dis; 2002 Sep; 44(1):101-7. PubMed ID: 12376039 [TBL] [Abstract][Full Text] [Related]
8. An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers. Nicodemo AC Braz J Infect Dis; 2003 Feb; 7(1):62-8. PubMed ID: 12807692 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. Anzueto A; Gotfried M; Wikler MA; Russo R; Nicholson SC Clin Ther; 2002 Jun; 24(6):906-17. PubMed ID: 12117081 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. Nicholson SC; Wilson WR; Naughton BJ; Gothelf S; Webb CD Diagn Microbiol Infect Dis; 2002 Sep; 44(1):117-25. PubMed ID: 12376041 [TBL] [Abstract][Full Text] [Related]
12. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Pfaller MA; Ehrhardt AF; Jones RN Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437 [TBL] [Abstract][Full Text] [Related]
13. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Jones RN; Andes DR; Mandell LA; Gothelf S; Ehrhardt AF; Nicholson SC Diagn Microbiol Infect Dis; 2002 Sep; 44(1):93-100. PubMed ID: 12376038 [TBL] [Abstract][Full Text] [Related]
14. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221 [TBL] [Abstract][Full Text] [Related]
15. Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. Sher LD; Poole MD; Von Seggern K; Wikler MA; Nicholson SC; Pankey GA Otolaryngol Head Neck Surg; 2002 Sep; 127(3):182-9. PubMed ID: 12297808 [TBL] [Abstract][Full Text] [Related]
16. Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia. Mandell LA; Jones RN Diagn Microbiol Infect Dis; 2002 Sep; 44(1):127-8. PubMed ID: 12376042 [No Abstract] [Full Text] [Related]
17. A critical review of the fluoroquinolones: focus on respiratory infections. Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ Drugs; 2002; 62(1):13-59. PubMed ID: 11790155 [TBL] [Abstract][Full Text] [Related]
18. Gatifloxacin: a review of its use in the management of bacterial infections. Perry CM; Ormrod D; Hurst M; Onrust SV Drugs; 2002; 62(1):169-207. PubMed ID: 11790160 [TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Balfour JA; Lamb HM Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103 [TBL] [Abstract][Full Text] [Related]
20. Safety profile of sparfloxacin in the treatment of respiratory tract infections. Rubinstein E J Antimicrob Chemother; 1996 May; 37 Suppl A():145-60. PubMed ID: 8737134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]